| The conundrum of depression clinical trials: one size does not fit all |
6 |
| Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial |
6 |
| Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review |
5 |
| Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2 |
5 |
| Personalized and precision medicine as informants for treatment management of bipolar disorder |
5 |
| The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies |
5 |
| A systematic review of the operational definitions for antipsychotic response in delusional disorder |
4 |
| Pharmacological treatment of sexual offenders in German outpatient treatment centers |
4 |
| Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis |
4 |
| Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial |
4 |
| Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine |
4 |
| Need to bleed? Clozapine haematological monitoring approaches a time for change |
4 |
| Trends of antidementia drugs use in outpatients with Alzheimer's disease in six major cities of China: 2012-2017 |
4 |
| Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis |
3 |
| A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia |
3 |
| Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma |
3 |
| Outcome and predictors of remission in bipolar-I patients experiencing manic episode and treated with oral antipsychotics and/or mood stabilizers: a prospective observational study in Italy |
3 |
| Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study |
3 |
| Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder |
3 |
| Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder |
3 |
| The use of (newer) antipsychotics in bipolar inpatients over a 17-year observation period |
3 |
| Continuity of treatment with benzodiazepines in dementia patients: an analysis of German health insurance claims data |
3 |
| Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression |
3 |
| Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies |
3 |
| Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression |
2 |
| Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation? |
2 |
| The effect of selective serotonin reuptake inhibitors on major adverse cardiovascular events: a meta-analysis of randomized-controlled studies in depression |
2 |
| A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder |
2 |
| The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder |
2 |
| Sex and body weight are major determinants of venlafaxine pharmacokinetics |
2 |
| Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6 |
2 |
| Antipsychotics in the general population and the driver population: comparisons from a population-based registry study |
2 |
| Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia: a pilot study |
2 |
| Antipsychotic drug exposure and risk of fracture: a systematic review and meta-analysis of observational studies |
2 |
| Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity |
2 |
| Long-term effects of paliperidone palmitate on hospital stay and treatment continuation |
2 |
| A personal account of depressive illness and its antidepressant treatment |
1 |
| Compliance in schizophrenia spectrum disorders: the role of clinical pharmacist |
1 |
| Comparison of the association of risperidone and quetiapine with deteriorating performance in walking and dressing in subjects with Parkinson's disease: a retrospective cohort study using administrative claims data |
1 |
| Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study |
1 |
| High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder |
1 |
| Add-on benzodiazepines for psychosis-induced aggression |
1 |
| Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia |
1 |
| Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder |
1 |
| Mineralocorticoid receptor-related markers and outcome of major depression: focus on blood pressure and electrolytes |
1 |
| A molecular pathway analysis informs the genetic risk for arrhythmias during antipsychotic treatment |
1 |
| The association between gabapentin and suicidality in bipolar patients |
1 |
| The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors |
1 |
| Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial |
1 |
| Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial |
1 |
